Drug Discovery World

DECEMBER 20, 2023

The company has 155 investigators who perform trials in around 20 therapeutic areas, including infectious disease, neurology, endocrinology, oncology, cardiology, dermatology and vaccines.

Clinical Research 52

Clinical Research Research Cardiology Dermatology 52

The Pharma Data

MARCH 13, 2022

(NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Additional Transaction Details.

Dermatology 52

Dermatology Cardiology Development Medicine 52

XTalks

AUGUST 2, 2023

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. is a global pharmaceutical company, working across both developed and emerging markets. Pfizer’s total global revenue from the Prevnar family of vaccines was $6.34

Sales 98

Sales Manufacturing FDA Approval Life Science 98

pharmaphorum

JANUARY 5, 2021

Anyone who proposed that a novel, deadly virus would spread, with a vaccine developed demonstrating 95% efficacy, and approved for patients in less than a year would have been scoffed at. These changes are likely to reduce only slowly in the Vaccine+ environment, and will not be entirely reversed.

Sales 105

Sales Marketing Production Vaccination 105

The Pharma Data

SEPTEMBER 15, 2020

Major revenue contributions through 2025 anticipated from Oncology, Vaccines, Rare Disease and Inflammation and Immunology. New stability, immunogenicity, and tolerability data for COVID-19 vaccine candidate, BNT162b2, presented. UPDATES ON COVID-19 DEVELOPMENT PROGRAMS. BNT162 mRNA-based Vaccine Program.

Vaccination 52

Vaccination Vaccine Gene Therapy Trials 52

The Pharma Data

APRIL 26, 2021

COVID-19 negatively impacted demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. Novartis is collaborating with Molecular Partners to develop, manufacture and commercialize two antiviral DARPin ® candidates, ensovibep (MP0420) and MP0423. Financials. First quarter.

Sales 40

Sales Medicine Production Manufacturing 40